期刊文献+

肝素对急性肺损伤大鼠基质金属蛋白酶2和9活性的影响 被引量:13

Effects of unfractionated heparin on expression of metalloproteinase-2 and -9 in acute lung injury rats
原文传递
导出
摘要 目的探讨肝素对急性肺损伤(ALI)大鼠体内基质金属蛋白酶(MMP-2、MMP-9)蛋白及mRNA表达的影响。方法18只雄性Wistar大鼠,按随机数字表法分成3组,每组6只。经尾静脉注射脂多糖(LPS)6mg/kg复制ALI大鼠模型;肝素组在注射LPS前15min经尾静脉注射普通肝素100U/kg,对照组注射等量生理盐水。分别于制模后1、3、6h取股静脉血,采用酶联免疫吸附试验(ELISA)测定血清中MMP-2、MMP-9蛋白表达;制模后6h处死动物,取左肺,应用实时荧光定量聚合酶链反应(qRT—PCR)检测肺组织中MMP-2及MMP-9的mRNA表达。结果与对照组比较,ALI组血清MMP-2(μg/L)、MMP-9(μg/L)蛋白表达增高,6h达到高峰(MMP-2:2.86±0.40比1.21±0.24,MMP-9:2.54±0.29比1.15±0.34,均P〈0.01);应用肝素后在6h时MMP-2、MMP-9蛋白表达明显降低(MMP-2:1.92±0.31比2.86±0.40,MMP-9:1.82±0.26比2.54±0.29,均P〈0.05)。制模后6h,ALI组肺组织MMP-2、MMP-9的mRNA表达明显高于对照组(MMP-2mRNA:1.88±0.09比1.00-±0.10,MMP-9mRNA:3.15±0.47比1.00±0.17,均P〈0.01);肝素组MMP-2、MMP-9的mRNA表达较ALI组明显降低(MMP-2mRNA:1.26±0.14比1.88±0.09,P〈0.01;MMP-9mRNA:2.06±0.68比3.15±0.47,P〈0.05),但仍高于对照组(均P〈0.05)。结论ALI大鼠体内MMP-2、MMP-9表达增加,肝素能够减少血清及肺组织中MMP-2、MMP-9的表达,从而减轻肺损伤。 Objective To determine the activation of matrix metalloproteinase ( MMP-2, MMP-9 ) in rats with acute lung injury (ALI) and the effects of unfraetionated heparin ( UFH ) on the levels. Methods Eighteen male Wistar rats were divided into control group, ALI group and UFH group, with 6 rats in each group by means of random number table. ALI was induced by administering a bolus injection of lipopolysacchafide (LPS) via the caudal vein at a dose of 6 mg/kg. In UFH group the rats were treated intravenously with 100 U/kg of UFH 15 minutes before the injection of LPS. In control group, the rats were treated with the same volume of normal saline. Serum levels of MMP-2 and MMP-9 were measured by onzymelinked immunosorbent assay (ELISA) at l, 3, 6 hours via femoral vein. Six hours after the injection of reagents, the rats were sacrificed and lung tissue samples were collected for mRNA analysis of the MMP-2 and MMP-9 by real-time fluorescence quantitate reverse transcription-polymerase chain reaction (qRT-PCR). Results Compared with control group, the content of MMP-2 (μg/L) and MMP-9 (μg/L) in serum of ALI group were increased, and reached the peak at 6 hours (MMP-2:2.86 ±0.40 vs. 1.21 ±0.24, MMP-9:2.54 ±0.29 vs. 1.15 ± 0.34, both P〈0.01 ); they were down-regulated in UFH group at 6 hours (MMP-2:1.92 ± 0.31 vs. 2.86 ± 0.40, MMP-9 : 1.82± 0.26 vs. 2.54 ± 0.29, both P〈0.05 ). Compared with control group, the mRNA expressions of MMP-2 and MMP-9 in the lung tissue of ALI group were increased at 6 hours (MMP-2 mRNA: 1.88 ± 0.09 vs. 1.00± 0.10, MMP-9 mRNA: 3.15 ± 0.47 vs. 1.00 ± 0.17, both P〈0.01 ); they were down-regulated in UFH group (MMP-2 mRNA: 1.26 ± 0.14 vs. 1.88 -+ 0.09, P〈0.01 ; MMP-9 mRNA: 2.06 ± 0.68 vs. 3.15± 0.47, P〈0.05 ), but still above the control group ( both P〈0.05 ). Conclusions The present study demonstrated that the level of MMP-2 and MMP-9 increased in rats with ALL UFH could exert protective effects by inhibiting expression of MMP-2 and MMP-9 in serum and lung tissue, in both mRNA and protein expression.
机构地区 [
出处 《中国危重病急救医学》 CAS CSCD 北大核心 2012年第10期608-611,共4页 Chinese Critical Care Medicine
基金 国家自然科学基金资助(81101411) 辽宁省科技厅药物源头创新研究课题(20071027-7) 辽宁省医学高峰建设工程项目(2010-1067) 辽宁省沈阳市科技计划项目(F10-205-1-01)
关键词 急性肺损伤 普通肝素 基质金属蛋白酶2 基质金属蛋白酶9 Acute lung injury Unfractionated heparin Matrix metalloproteinase-2 Matrix metalloproteinase-9
  • 相关文献

参考文献7

二级参考文献79

  • 1季宪飞,黄亮江.细胞黏附分子与急性肺损伤[J].中国危重病急救医学,2004,16(7):444-446. 被引量:8
  • 2艾宇航,张丽娜,龚华,徐道妙,赵双平,陈江辉.低分子肝素治疗脓毒症的前瞻性临床研究[J].中国危重病急救医学,2005,17(12):736-739. 被引量:43
  • 3栾正刚,娜拉.普鲁,章志丹,马晓春.低分子肝素和阿司匹林对急性肺损伤的治疗作用[J].中国危重病急救医学,2006,18(8):456-458. 被引量:17
  • 4樊毫军,刘书盈,张健鹏,刘又宁.静脉注射内毒素致大鼠急性肺损伤模型的病理生理学指标评价[J].中国危重病急救医学,2006,18(8):485-487. 被引量:20
  • 5Kinasewitz GT,Yan SB,Besson B,et al.Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis,regardless of causative micro-organism[ISBCTN74215569].Crit Care,2004,8:R82-90.
  • 6Bone RC,Balk RA,Cerra FB,et al.Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.The ACCP/SCCM Consensus Conference Committee.American College of Chest Physicians/Society of Critical Care Medicine.Chest,1992,101:1644-1655.
  • 7Bernard GR,Vincent JL,Laterre PF,et al.Efficacy and safety of recombinant human activated protein C for severe sepsis.N Engl J Med,2001,344:699-709.
  • 8Monaet X,Lamia B,Anguel N,et al.Rapid and beneficial bemodynamic effects of activated protein C in septic shock patients.Intensive Care Med,2005,31:1573-1576.
  • 9Abraham E,Laterre PF,Garg R,et al.Dretrecogin alfa (activated) for adults with severe sepsis and a low risk of death.N Engl J Meal,2005,353:1332-1341.
  • 10Schippar HG,Jenkins CS,Kahle LH,et al.Antithrombin-Ⅲ transfusion in disseminated intravaseular coagulation.Lancet,1978,1:854-856.

共引文献90

同被引文献168

引证文献13

二级引证文献121

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部